Laboratory of Cerebrovascular Diseases

Stroke and neuroprotection

Stroke is a major public health issue worldwide. In Switzerland, it is the third cause of death and the main cause of disability in adults. More than 600 patients are admitted every year into the CHUV in the Service of Neurologie - Stroke Center following an acute stroke or transient ischemic attack. The only available treatment for acute ischemic stroke is acute revascularization therapy (intravenous thrombolysis and endovascular intra-arterial clot removal) within the first hours after symptom onset. An increasing number of patients now benefit from this treatment but the total number, approximately 10%, remains low and a specific alternative treatment for the majority of patients is lacking.

Our lab, directed by Pr Lorenz Hirt, is studying ischemic damage to the brain as well as endogenous tolerance mechanisms, which exist in the brain, with the aim of identifying new therapeutic targets and developing new strategies to protect the suffering brain tissue in the case of stroke.

Using an experimental approach both in vitro and in vivo in rodents, we study mechanisms of cell death and neuroprotection after stroke. We are also investigating potential biomarkers for outcome prediction in these models.

Our laboratory is part the Department of Clinical Neurosciences of the CHUV. We are hosted by and collaborate actively with the Department of Fundamental Neurosciences.

 Last updated on 07/02/2018 at 18:47